GlassScriptPhysician profile
Carol M Holder
NPI 1184803066
$2,375.96
in general payments reported to CMS, 2019-2025
20 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $444 · 2022: $527 · 2023: $335 · 2024: $498 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $635.19 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.85 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $145.52 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $128.74 | 2022-2023 | Austedo Xr |
| Alkermes, INC. | $99.75 | 2022 | |
| Medicure Pharma INC. | $99.75 | 2025 | Zypitamag |
| Axonics, INC. | $94.56 | 2024 | Axonics |
| Amgen INC. | $72.58 | 2021 | |
| Alnylam Pharmaceuticals INC. | $55.56 | 2024 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $51.96 | 2024 | |
| Novo Nordisk INC | $41.39 | 2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $35.75 | 2025 | Voquezna |
| Exact Sciences Corporation | $26.40 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.80 | 2025 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.30 | 2023 | |
| Pfizer INC. | $18.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2022 | |
| Neurocrine Biosciences, INC. | $13.89 | 2022 | |
| Lilly USA, LLC | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Holder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.